Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on Autoimmunity
Presentation Title: Targeting the Neonatal Fc Receptor (FcRn) for the Treatment of Pathogenic IgG Antibody Diseases
Session Title: IVIG MIMETICS: Potential Next Generation Biologics in Autoimmune Diseases
Location: Auditorium VIII, Parallel Session
The slides will be made available shortly after the presentation on the
The presentation will focus on a discussion of the broad potential of FcRn antagonists in rare auto- and allo-immune diseases, and describe details of the discovery and development of M281, Momenta’s anti-FcRn therapeutic. The presentation will highlight the unique design attributes of M281, including best-in-class potency and pH insensitivity achieved via proprietary somatic hypermutation technology, fully human IgG scaffold to minimize immunogenic potential, and state-of-art aglycosylation variant design to eliminate any effector function potential. Dr. Manning will present X-ray crystallographic data revealing a unique structural basis for best-in-class affinity, extensive pre-clinical pharmacology and toxicology evaluation, and Phase 1 human clinical trial data that support the potential of M281 as a best-in-class FcRn antagonist.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release. The company’s logo, trademarks, and service marks are the property of
MacDougall Biomedical Communications
Source: Momenta Pharmaceuticals, Inc.